PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 269 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR AI is impacting cancer care, but also the environment September 25, 2025 Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests May 9, 2019 Proof of Concept for the Safety and Immunogenicity of Lymph Node... January 18, 2024 Preoperative ctDNA Levels Are Detectable in the Majority of Patients with... July 5, 2021 Load more HOT NEWS Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and... Breast Cancer Vaccine Has Eliminated Cancer In Its First Human Patient No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... For Children with Retinoblastoma, Disparities Seen across the Globe
